Neucardin Trial :Treatment Study for Stable Chronic Heart Failure

Gender Preference	None
Age Group	18 - 99 years
Research Start Date	May 1, 2012
Research End Date	July 17, 2013
Principal Investigator	KellyAnn Light-McGroary, MD
Description	Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure (ZS-01-210) Recombinant human Neuregulin-1 (rhNRG-1, also called ) is a 61 amino acid peptide that acts directly on damaged heart muscle cells to restore their structure and function. This randomized, parallel, placebo-controlled, double-blind, multi-center study will assess the safety and efficacy of rhNRG-1 also known as Neucardin as a treatment for stable chronic heart failure. Please refer to www.clinicaltrials.gov identifier NCT01251406 for more information
Contact Info	Cardiomyopathy Treatment Program Cynthia Larew, RN BSN phone: 319-356-1028 fax: 319-356-7087 email: cynthia-larew@uiowa.edu
Keywords	span itemProp='description'>cardiac disease ; cardiomyopathy ; CHF ; congestive heart failure ; Enter keyword ; heart failure ; left ventricular dysfunction ; left ventricular systolic dysfunction ; low ejection fraction ;

Contact